MetaCap

Drugs Made In America Acquisition (DMAA) vs SC II Acquisition (SCII)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.

Summary

Drugs Made In America Acquisition is the larger company by market cap ($263.4 million vs $253.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Head-to-head

DMAA versus SCII key metrics
MetricDMAASCII
Share price$10.85$10.17
Market cap$263.40M$253.21M
1-day change+0.18%0.00%
P/E ratio (TTM)60.28—
EPS (TTM)$0.18—
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$10.89$10.18
52-week low$10.26$9.90
Distance from 52-week high-0.37%-0.12%
Average volume21.64K19.04K
Shares outstanding24.28M17.50M
SectorFinancial ServicesFinancial Services
IndustryShell CompaniesShell Companies

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Drugs Made In America Acquisition

DMAA stock →

Drugs Made In America Acquisition Corp. does not have significant operations.

Financial Services · Shell Companies

About SC II Acquisition

SCII stock →

SC II Acquisition Corp. focuses on effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses.

Financial Services · Shell Companies

DMAA vs SCII FAQ

Which is bigger, Drugs Made In America Acquisition or SC II Acquisition?

Drugs Made In America Acquisition (DMAA) is larger, with a market capitalization of $263.40M compared with $253.21M for SC II Acquisition (SCII).

Are Drugs Made In America Acquisition and SC II Acquisition in the same industry?

Yes. Both are classified in the Shell Companies industry within the Financial Services sector.

More comparisons